Cartesian Therapeutics Future Growth
Future criteria checks 0/6
Cartesian Therapeutics's revenue is forecast to decline at 23.2% per annum while its annual earnings are expected to grow at 5.2% per year. EPS is expected to grow by 34.4% per annum.
Key information
5.2%
Earnings growth rate
34.4%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | -23.2% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 11 | -103 | -57 | N/A | 4 |
| 12/31/2025 | 7 | -80 | -38 | N/A | 6 |
| 12/31/2024 | 40 | -86 | -3 | N/A | 6 |
| 9/30/2024 | 48 | -282 | -48 | -40 | N/A |
| 6/30/2024 | 54 | -267 | -65 | -63 | N/A |
| 3/31/2024 | 26 | -288 | -59 | -58 | N/A |
| 12/31/2023 | 26 | -257 | -51 | -51 | N/A |
| 9/30/2023 | 127 | -1 | -59 | -58 | N/A |
| 12/31/2022 | 111 | 35 | -33 | -32 | N/A |
| 12/31/2021 | 85 | -26 | -61 | -60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RNAC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RNAC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RNAC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RNAC's revenue is expected to decline over the next 3 years (-23.2% per year).
High Growth Revenue: RNAC's revenue is forecast to decline over the next 3 years (-23.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RNAC's Return on Equity is forecast to be high in 3 years time